Skip to main content
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: JAMA Neurol. 2016 May 1;73(5):535–541. doi: 10.1001/jamaneurol.2016.0031

Table 4.

Individual AP Risks Relative to Quetiapine in AP-Exposed Patients

Group HR (95% CI) P Valuea
Intention-to-treat analysis
 Quetiapine fumarate 1 [Reference] NA
 Haloperidol 1.85 (1.41–2.43) <.001
 Other typical AP 1.54 (1.01–2.36)   .047
 Olanzapine 1.47 (1.20–1.79) <.001
 Risperidone 1.30 (1.08–1.56)   .006
 Other atypical AP 1.23 (0.69–2.19)   .49
Exposure-only analysis
 Quetiapine 1 [Reference] NA
 Haloperidol 2.33 (1.62–3.36) <.001
 Other typical AP 1.39 (0.70–2.79)   .35
 Olanzapine 1.36 (1.01–1.83)   .04
 Risperidone 1.42 (1.11–1.82)   .005
 Other atypical AP 1.30 (0.58–2.89)   .52

Abbreviations: AP, antipsychotic; HR, hazard ratio; NA, not applicable.

a

Obtained from testing for the significance of the covariate estimates obtained from the corresponding Cox proportional hazards regression model.